N/A
Completed N=281
Examining Racial and SocioEconomic Disparities (ERASED) in Chronic Low Back Pain Study
Back Pain Lower Back Chronic
Source: ClinicalTrials.gov NCT03338192 ↗
Enrolled (actual)
281
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Average Clinical Pain Severity — 5.1; 3.9 units on a scale
Summary
It remains unclear whether certain disadvantaged subgroups of society may be at heightened risk for poor chronic low back pain (cLBP) outcomes. The overall aim of this study is to incorporate a socioeconomic framework to characterize racial differences in cLBP severity and disability. Further, guided by the theory of fundamental causes, we aim to examine racial and socioeconomic status differences in biopsychosocial predictors of cLBP outcomes, particularly endogenous pain modulation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Clinical Pain Severity |
5.1; 3.9 | — |
| SECONDARY Average Pain Threshold (Heat) |
39.96; 40.54 | — |
| SECONDARY Average Pain Tolerance (Heat) |
42.50; 44.61 | — |
| SECONDARY Difference in Temporal Summation of Pain (Mechanical) |
20.16; 12.68 | — |
| SECONDARY Difference in Pressure Pain Thresholds Assessed Using Conditioned Pain Modulation |
-7.82; -10.80 | — |
| SECONDARY Total Level of C-reactive Protein |
6394.52; 5040.71 | — |
| SECONDARY Total Level of Fibrinogen |
1656.55; 1417.26 | — |
| SECONDARY Total Level of Serum Amyloid A |
12224.88; 9109.35 | — |
| SECONDARY Total Level of Vitamin D |
20.5; 26.9 | — |
| SECONDARY Total Level of Oxytocin |
181.54; 192.71 | — |
| SECONDARY Sleep Quality |
12.08; 12.12 | — |
| SECONDARY Self-reported Disability |
53.40; 41.96 | — |
| SECONDARY Evoked Pain With Movement |
31.01; 13.33 | — |
| SECONDARY Functional Performance |
8.95; 9.82 | — |
Eligibility Criteria
Inclusion Criteria
- Chronic low back pain that has been going on consistently for the last 6 months.
Exclusion Criteria
- Surgery (fusion, Laminectomy) in the last year, accident or trauma in the last year, uncontrolled high blood pressure, heart disease, cancer, diabetes HbA1c > 7%, Ankylosing Spondylitis, Infection, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Stroke, Seizure (non-epileptic), Systemic Lupus Erythematosus, Fibromyalgia, Raynaud's disease, Major Depression/Bipolar Disorder, HIV
Data sourced from ClinicalTrials.gov (NCT03338192). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.